MedTrace Logo

Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB

NCT00204529 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 901

Last updated 2017-05-03

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant melanoma in stage IIA (T3a) - IIIB.

A total of 880 will be randomized up to three months after first surgical management of their melanoma to either: PEG-IFN-α-2a or low-dose interferon-α-2a.

Conditions

Interventions

DRUG

pegylated interferon-alpha-2a

DRUG

interferon-alpha-2a

Sponsors & Collaborators

  • Dermatologic Cooperative Oncology Group

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Claus Garbe, MD · Skin Cancer Program, Department of Dermatology, University of Tübingen, Liebermeisterstr. 20, 72076 Tübingen, Germany

  • Hubert Pehamberger, MD · Department of Dermatology, University Hospital Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2013-05-31
Completion
2016-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00204529 on ClinicalTrials.gov